Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study
Matthew S. Davids(Dana-Farber Cancer Institute), Yifan Zhai(Unknown), Boyd Mudenda, Tanya Siddiqi(City Of Hope National Medical Center), Zvenyslava Maslyak(Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine), Ivan Muzhychuk, Lei Fu, Allison Winter(Cleveland Clinic), Laura A. Glass, Asher Chanan‐Khan(WinnMed), Hengbang Wang, Vinod Ganju(Peninsula Health), Min Yu(University of Maryland, Baltimore), Iryna Kriachok(National Cancer Institute), Б. А. Бакиров(Bashkir State Medical University), Mohammad Ahmad, Asit K. De, Iurii Osipov, Alexander G. Myasnikov(Petrozavodsk State University), Olena Kyselova, Paula Marlton(The University of Queensland), Olga Samoylova(Nizhny Novgorod Regional Clinical Hospital named after Semashko), Elena Borisenkova(Murmansk Regional Clinical Hospital), Larysa Nogaieva(Cherkasy State Technological University), Hanna Usenko(Regional Clinical Hospital named after II Mechnikov), Dajun Yang(Ascendis Pharma (Denmark)), Tamila Lysa, Ben Paudyal, Tetiana Perekhrestenko, Mingyu Li, Zi Chen(Dartmouth College), Vladimir Ivanov, Т. С. Константинова(Regional Children's Clinical Hospital No. 1), Олена Карпенко, Nashat Gabrail(Gabrail Cancer Center), Robert L. Winkler(Technische Universität Darmstadt), Olga Uspenskaya, Andrew Proidakov(Republican Oncological Clinical Dispensary)
Cited by 16
Related Papers
Genomic responses in mouse models poorly mimic human inflammatory diseases
|Proceedings of the National Academy of Sciences|2013|3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752